A History of Science


The history of Agendia is like a history of genomic science and the development of personalized cancer treatment. Founded in 2003 by Dr. Bernhard Sixt, Professor René Bernards and Dr. Laura van ‘t Veer, Agendia was, and still remains a company focused on the practical application of microarray technology and gene expression profiling for the benefit of cancer patients around the world. The key milestones in Agendia history are chronicled below:

 

Agendia Milestones                    

 

2009

  • MammaPrint added to the prestigious St. Gallen’s International Oncology Guidelines for Primary Therapy of Early Breast Cancer.
  • CLIA registration of Agendia’s Irvine, California laboratory.


2008

  • Agendia launches its diagnostic test TargetPrint for breast cancer patients.
  • Due to expansion of the company, Agendia moves it’s headquarters to the Amsterdam Science Park in spring 2008.
  • Foundation of Agendia Inc. in the US.


2007

  • Major studies and trials initiated for further application and validation of new diagnostic oncology tests in breast cancer and other types of cancer.
  • Agendia announces discovery of new gene expression profile for colon cancer.
  • CLIA registration of Agendia laboratory.
  • MammaPrint acquires 510K clearance from the FDA under the newly defined IVDMIA regulations, and a second clearance for the MammaPrint sampling and shipping procedure at room temperature.


2006

  • CupPrint acquires CE marking.


2005

  • ISO 17025 accreditation of Agendia laboratory.  
  • MammaPrint acquires CE marking.  
  • Development of global network of subsidiary companies and agents/distributors begins.  
  • Agendia launches second commercial test, CupPrint.


2004

  • Agendia launches its first clinically validated product, MammaPrint, based on the gene signature resulting from Bernards and van´t Veer’s original work.


2003

  • Agendia launches its DiscoverPrint service.
  • Foundation of Agendia by Dr. Bernhard Sixt, Dr. Rene Bernhards and Dr. Laura van`t Veer.


2002

  • Van ‘t Veer and Bernards publish an mRNA based method for genomic profiling that predicts the clinical outcome of breast cancer (van´t Veer et al, Nature, vol 415, 31 January 2002, 530-535, van de Vijver et al., New England Journal of Medicine, vol 347, no 25, 19 December 2002).